Pentadeca Arginate (PDA)
PDA, Pentadecapeptide Arginate, BPC-157 Arginate, Arginate salt of BPC-157, "PDA peptide"
The Ground Truth Score
four plain questions, never one numberAnimal data with an arginate twist nobody has actually tested in humans
Bottom line
PDA is a salt-swapped BPC-157 sold on rodent data and clinic marketing; the arginate form itself has zero published human studies, and even its parent peptide has only a handful of tiny uncontrolled pilots.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Reported (not prescribed) protocols mirror BPC-157: roughly 250-500 mcg up to ~1 mg per subcutaneous injection.
Reported, not prescribed. Verify your vial and your math.
First documented human use
No controlled human trial of Pentadeca Arginate has ever been completed or published, a PubMed search for "pentadeca arginate" and a ClinicalTrials.gov search both return zero results (verified June 2026). The arginate salt form appears to have entered gray-market/compounding-clinic use around 2023-2024 after the FDA placed BPC-157 on its Category 2 bulk-substance list (Sept 2023), as a rebranded alternative, not from any registered first-in-human study. The closest documented human exposure is to the parent peptide BPC-157 (acetate), first appearing in small human reports around 2021 (Lee & Padgett intra-articular knee case series).
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- Marketed as the same 15-amino-acid sequence as BPC-157 (GEPPPGKPADDAGLV) but as an arginine salt instead of acetate.
- Vendors claim the arginate counterion improves peptide stability and bioavailability, though no head-to-head human or animal data is published to support this.
- Promoted for soft-tissue, tendon, ligament and gut-lining repair, extrapolated entirely from BPC-157 rodent studies.
- Positioned as a compliant successor to BPC-157 after the FDA's 2023 compounding restriction, marketed heavily by peptide clinics and med spas.
- Claimed to work via angiogenesis (VEGFR2/eNOS), fibroblast activity and a shift from inflammatory M1 to reparative M2 macrophages.
The data behind each bullet
What actually backs it
No published human study has ever investigated pentadeca arginate as a distinct molecule; the arginate-specific evidence base is empty.
A PubMed search for the exact phrase 'pentadeca arginate' returns zero results, and ClinicalTrials.gov returns zero matching studies (both verified June 2026). All efficacy claims are borrowed wholesale from BPC-157 preclinical work.
PubMed: 'pentadeca arginate' (0 results) ↗The parent peptide BPC-157 has extensive rodent data but only a few small, uncontrolled human studies, no RCTs.
A 2025 systematic review in orthopaedic sports medicine screened 544 articles and found just one clinical study met inclusion (an uncontrolled retrospective knee-pain case series); the other ~35 were animal models. Two additional small human pilots (interstitial cystitis n=12; IV PK in 2 healthy adults) exist but are uncontrolled.
PubMed: BPC-157 pentadecapeptide human ↗No PDA-specific or BPC-157-arginate trial is registered anywhere; only two BPC-157 (acetate) trials exist on ClinicalTrials.gov.
ClinicalTrials.gov returns 0 results for 'pentadeca arginate' and only 2 for 'BPC-157', an older safety/PK study (NCT02637284, active not recruiting) and a Phase 2 hamstring-strain trial (NCT07437547, recruiting). Neither studies the arginate salt.
ClinicalTrials.gov: BPC-157 search ↗The FDA flagged BPC-157 (and by extension its salts) for safety/immunogenicity and impurity concerns, restricting compounding.
In Sept 2023 the FDA added BPC-157 to its Category 2 bulk-drug-substance list, citing potential immunogenicity for some routes, peptide-impurity complexities, and limited safety data. Reports indicate FDA removed it from Category 2 in April 2026, which does not equal approval. PDA inherits this regulatory posture.
FDA: Bulk Drug Substances That May Present Significant Safety Risks ↗Assumed mechanism (angiogenesis, NO/eNOS signaling, fibroblast/collagen support, M1-to-M2 macrophage shift) is derived from BPC-157 animal models, not from human PDA data.
Narrative and literature reviews describe VEGFR2-Akt-eNOS activation, ERK1/2-driven proliferation, and cytoprotective pathways in preclinical models; authors explicitly conclude BPC-157 should be considered 'investigational' until human trials exist.
PubMed: BPC 157 mechanism multifunctionality review ↗Mechanism
How it's assumed to work
Assumed (no human PDA data). PDA is presumed to act identically to BPC-157 since it is the same peptide sequence as an arginine salt. In animal models the parent peptide is proposed to accelerate healing by promoting angiogenesis through the VEGFR2-Akt-eNOS pathway, increasing nitric-oxide availability and local blood flow, stimulating fibroblast migration and collagen organization (FAK-paxillin signaling), and shifting macrophages from a pro-inflammatory M1 toward a reparative M2 phenotype. The arginate counterion is marketed as improving stability/bioavailability, but that specific claim is unproven in any published study.
Dosing & handling
What users and clinicians report
Reported (not prescribed) protocols mirror BPC-157: roughly 250-500 mcg up to ~1 mg per subcutaneous injection. A common pattern is a loading phase of 500 mcg-1 mg daily for the first 7-10 days of an acute injury, then a maintenance phase of 500 mcg-1 mg two to three times per week. Vials are frequently 10-15 mg; a 15 mg vial reconstituted with ~3 mL bacteriostatic water yields 5 mg/mL, so ~10 units (0.1 mL) on an insulin syringe is ~500 mcg. Some clinics also sell oral/capsule versions for gut-focused use, though injection is the dominant route.
These numbers come from vendor and clinic marketing and community practice, NOT from any dose-finding human trial, no validated human dose exists for the arginate form. Vial concentrations vary, so confirm the actual mg/mL from the label and a vial photo before doing syringe math; a wrong reconstitution volume changes the dose several-fold. Because product is compounded or research-grade, the stated mg on the label may not match contents.
Timing & food
Reported timing is flexible and not evidence-based. Many users inject subcutaneously near the injury site (or in the abdomen for systemic/gut goals), often once or twice daily during a loading phase. Timing relative to food is generally considered unimportant for subcutaneous injection given the systemic mechanism; oral/gut-targeted versions are sometimes taken on an empty stomach on the theory of more direct GI-lining contact. None of this timing rationale is supported by human pharmacokinetic data for PDA.
Half-life
Short. For the parent peptide BPC-157, reported plasma half-life is under ~30 minutes, and in the small IV human pilot plasma concentrations returned to baseline within 24 hours. Reviewers note a paradox: despite the brief half-life, the downstream angiogenic/repair processes it is claimed to trigger appear (in animal models) to persist for weeks. No PK data exists for the arginate salt specifically.
Reconstitution sensitivity
Treat as a standard lyophilized peptide. Reconstitute with bacteriostatic (or sterile) water, swirl gently down the vial wall rather than shaking to avoid shearing the peptide, and do not inject the stream directly onto the powder. Store lyophilized vials cold; once reconstituted, refrigerate at 2-8 C (36-46 F) and use within several weeks. For long-term storage of unreconstituted powder, -20 C is reported. Protect from light, heat, and repeated freeze-thaw. Gray-market product handling/cold-chain during shipping is an additional unverifiable variable.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
Moderate but heavily skewed. There is a large and growing volume of online content about PDA, but the overwhelming majority is med-spa, peptide-clinic, and vendor marketing (often with affiliate/sales intent), not independent user reports. Genuine grassroots forum/community discussion of PDA specifically is far thinner than for BPC-157, since PDA is a recent rebrand. Most clinic 'patient recovery' testimonials are marketing, not independent data, and should be discounted.
Consistency
Where independent anecdote does exist, reports skew positive for soft-tissue and gut recovery but are inconsistent and rarely controlled for natural healing, concurrent rehab, or co-administered peptides. A meaningful subset of users report no clear benefit. The positive-leaning tilt is exactly what you would expect from a mechanism marketed during acute-injury windows when tissue heals anyway.
Source credibility
Low source credibility overall. The dominant voices are commercial (clinics selling injections, peptide vendors selling vials). Independent, disinterested reports are sparse and PDA-specific reports are even sparser. After discounting affiliate/vendor sources, the credible independent signal for the arginate form specifically is faint, most of what looks like evidence is really marketing volume.
- Commonly reported (anecdote, not proof): faster-feeling recovery from tendon, ligament, and muscle injuries when used during the acute window, often alongside PT, making attribution to the peptide difficult.
- A recurring theme is gut/GI relief (reflux, IBS-type symptoms, general 'gut healing'), echoing BPC-157's gastric-protective marketing; this is largely subjective self-report.
- Users frequently note it is well tolerated, with the main complaints being injection-site soreness or redness rather than systemic side effects.
- A skeptical minority reports no noticeable difference versus prior BPC-157 use and questions whether the 'arginate upgrade' is anything more than a marketing relabel to sidestep the FDA restriction.
Placebo risk, Moderate
Moderate. The headline use-cases are subjective endpoints prone to placebo and natural-recovery confounding, pain, perceived recovery speed, gut comfort, typically used right after an injury when healing happens regardless, alongside rehab and other peptides. It is not rated High only because a few outcomes are at least semi-objective (e.g., the parent peptide's tiny pilots reported imaging/clinical resolution in interstitial cystitis), but no blinded, placebo-controlled PDA data exists to separate real effect from expectation.
Risk panel
What could go wrong
Adverse events
In the handful of small, uncontrolled human BPC-157 exposures (intra-articular, intravesical, and IV up to ~20 mg in 2 adults), no serious adverse events were reported, but these involve only a few dozen people total, none using the arginate form, and adverse events were not systematically collected. Commonly reported minor effects are injection-site reactions (redness, soreness, swelling). There is no long-term human safety dataset.
Theoretical concerns
Because the assumed mechanism is pro-angiogenic, the central theoretical concern is unwanted blood-vessel growth, e.g., feeding an occult tumor or affecting proliferative retinopathy. Excess nitric-oxide signaling and possible effects on drug metabolism have also been raised in reviews. None of these have been demonstrated or refuted in humans, which is precisely the problem.
Contraindications
No human contraindication list exists because no human trials define one. Caution is reasonable for anyone with an active or recent cancer (given the angiogenesis mechanism), during pregnancy/breastfeeding (no data), and for those on medications where altered metabolism could matter. The FDA specifically flagged immunogenicity risk for certain injection routes.
Honest unknowns
Almost everything material is unknown: human pharmacokinetics of the arginate salt, whether the arginate counterion changes anything clinically vs acetate, real adverse-event rates, long-term oncologic/cardiovascular safety, gray-market product purity and actual peptide content, and whether any benefit exceeds placebo. Product identity and dose accuracy are a real risk since these are compounded/research-grade, not FDA-manufactured.
Confound watch
Users almost never run PDA in isolation. It is typically stacked with TB-500/BPC-157 acetate, GHK-Cu, growth-hormone secretagogues (CJC/ipamorelin, tesamorelin), TRT, and an aggressive rehab/PT, sleep, and nutrition push during an injury. Natural injury healing over the same 4-8 week window is the biggest confounder, tendons and gut linings recover on their own timeline, making any peptide look effective.
History
Discovery → first use → status
- 1991-1993BPC-157 (the parent pentadecapeptide, a partial sequence from human gastric juice) first described and synthesized in Croatian research.
- ~2010sBPC-157 (acetate) spreads through bodybuilding/biohacker communities as a gray-market 'healing peptide' on the strength of rodent studies.
- 2021First small human report on the parent peptide: Lee & Padgett retrospective case series of intra-articular BPC-157 for chronic knee pain (uncontrolled).
- Sept 2023FDA places BPC-157 on Category 2 bulk-substance list, restricting compounding, the regulatory event that motivated rebranding to the arginate salt (PDA).
- 2023-2024'Pentadeca Arginate' / 'PDA' emerges as a compounding-clinic and med-spa product, marketed as a more-stable, compliant alternative to BPC-157.
- 2024-2025Additional small uncontrolled human pilots of BPC-157 appear (interstitial cystitis; IV pharmacokinetics in 2 adults); still no RCT and still nothing on the arginate form.
- 2025Systematic reviews (orthopaedic sports medicine; gastroenterology) confirm the human evidence base is essentially one small case series amid dozens of animal studies.
- April 2026FDA reportedly removes BPC-157 from the Category 2 list (not an approval); PDA-specific human evidence remains nonexistent.
Verification
The COA standard, applied
Verified June 2026: PubMed phrase search 'pentadeca arginate' = 0 results; ClinicalTrials.gov 'pentadeca arginate' = 0 results, 'BPC-157' = 2 trials (none on the arginate salt). BPC-157 human evidence cross-checked against 2025 systematic reviews (orthopaedic sports medicine; gastroenterology) and a 2025 narrative review, which independently report only ~3 small uncontrolled human studies. FDA Category 2 listing (Sept 2023) confirmed via FDA compounding page; reported April 2026 removal noted as secondary sourcing, not confirmed on FDA.gov directly. All efficacy/mechanism claims here are explicitly attributed to BPC-157 preclinical work, not to PDA-specific human data.
The full verification standard →Sources
Where this comes from
- PubMed, 'pentadeca arginate' (0 results: the empty page is the headline finding) ↗· No published literature exists for the arginate molecule as a distinct entity.
- PubMed. BPC-157 pentadecapeptide human (~51 results) ↗· Parent-peptide literature; reviews confirm only a few small uncontrolled human studies.
- ClinicalTrials.gov. BPC-157 / pentadeca arginate search ↗· 0 trials for 'pentadeca arginate'; 2 for BPC-157 (NCT02637284 PK/safety; NCT07437547 Phase 2 hamstring), none on the arginate salt.
- FDA. Bulk drug substances that may present significant safety risks (compounding) ↗· Basis for BPC-157's Category 2 listing (Sept 2023): immunogenicity, impurity, and limited-safety-data concerns; PDA inherits this posture.
- PubMed. BPC-157 multifunctionality / medical application review ↗· Preclinical mechanism (angiogenesis/eNOS, cytoprotection); reviewers call BPC-157 investigational pending human trials.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.